Iambic Therapeutics is a clinical-stage biotechnology company that discovers and develops small-molecule oncology drugs using an AI-driven drug discovery platform. The company operates a dual-track business model, advancing a wholly owned drug pipeline while collaborating with pharmaceutical partners on external discovery programs. Iambic's platform integrates predictive and generative AI models with automated robotic laboratories that synthesize and test compounds, generating proprietary experimental data in a continuous feedback loop. The company's lead internal program is IAM1363, an oral, brain-penetrant HER2 inhibitor in clinical trials for HER2-altered solid tumors. Its other wholly owned programs include IAM217, a KIF18A inhibitor, and IAM-C1, a dual CDK2/4 inhibitor targeting breast cancer. Iambic partners with pharmaceutical companies, including AbbVie and Takeda, to identify drug candidates in exchange for upfront fees, research reimbursements, milestone payments, and commercial royalties. Iambic uses this collaboration revenue to partially fund its internal drug development pipeline.